tiprankstipranks
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
US Market
VYGR
Voyager Therapeutics
RESEARCH TOOLSreports

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

1,341 Followers
See the Price Targets and Ratings of:

VYGR Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Voyager
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VYGR Stock 12 Month Forecast

Average Price Target

$14.67
▲(270.45% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $14.67 with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 270.45% change from the last price of $3.96.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,5.753846153846155,7.357692307692308,8.961538461538462,10.565384615384616,12.16923076923077,13.773076923076923,15.376923076923077,16.980769230769234,18.584615384615386,20.18846153846154,21.792307692307695,23.396153846153844,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.9592307692307696,5.768461538461539,6.577692307692308,7.386923076923077,8.196153846153846,9.005384615384616,9.814615384615385,10.623846153846154,11.433076923076923,12.242307692307692,13.051538461538462,13.86076923076923,{"y":14.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.15,4.446153846153846,4.742307692307692,5.038461538461538,5.334615384615384,5.63076923076923,5.926923076923077,6.223076923076923,6.519230769230769,6.815384615384615,7.111538461538461,7.407692307692308,7.703846153846154,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$14.67Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on VYGR
Samantha Semenkow
Citi
Citi
$11
Buy
177.78%
Upside
Reiterated
03/23/26
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
Truist Financial Analyst forecast on VYGR
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), Voyager Therapeutics (NASDAQ: VYGR) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
H.C. Wainwright Analyst forecast on VYGR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$25
Buy
531.31%
Upside
Reiterated
03/17/26
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
Wedbush Analyst forecast on VYGR
Yun Zhong
Wedbush
Wedbush
$8
Buy
102.02%
Upside
Assigned
03/11/26
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
Wells Fargo Analyst forecast on VYGR
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$10
Buy
152.53%
Upside
Reiterated
03/11/26
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Guggenheim Analyst forecast on VYGR
Debjit Chattopadhyay
Guggenheim
Guggenheim
$22
Buy
455.56%
Upside
Reiterated
03/10/26
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR)
Canaccord Genuity Analyst forecast on VYGR
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$12
Buy
203.03%
Upside
Reiterated
03/10/26
Voyager Therapeutics: Undervalued Neurology Pipeline With High‑Reward 2026 Catalysts Supports Buy Rating
TD Cowen Analyst forecast on VYGR
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR) and West Pharmaceutical Services (NYSE: WST)
Leerink Partners Analyst forecast on VYGR
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
$11
Buy
177.78%
Upside
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Voyager Therapeutics (NASDAQ: VYGR)
Oppenheimer Analyst forecast on VYGR
Jay Olson
Oppenheimer
Oppenheimer
$18
Buy
354.55%
Upside
Reiterated
10/02/25
Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer
Robert W. Baird Analyst forecast on VYGR
Jack Allen
Robert W. Baird
Robert W. Baird
$18
Buy
354.55%
Upside
Reiterated
07/17/25
Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on VYGR
Samantha Semenkow
Citi
Citi
$11
Buy
177.78%
Upside
Reiterated
03/23/26
Voyager Therapeutics: Early-Stage Tau Program Optionality Drives High-Risk, High-Upside Buy Rating
Truist Financial Analyst forecast on VYGR
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/17/26
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), Voyager Therapeutics (NASDAQ: VYGR) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
H.C. Wainwright Analyst forecast on VYGR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$25
Buy
531.31%
Upside
Reiterated
03/17/26
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
Wedbush Analyst forecast on VYGR
Yun Zhong
Wedbush
Wedbush
$8
Buy
102.02%
Upside
Assigned
03/11/26
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
Wells Fargo Analyst forecast on VYGR
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$10
Buy
152.53%
Upside
Reiterated
03/11/26
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
Guggenheim Analyst forecast on VYGR
Debjit Chattopadhyay
Guggenheim
Guggenheim
$22
Buy
455.56%
Upside
Reiterated
03/10/26
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR)
Canaccord Genuity Analyst forecast on VYGR
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$12
Buy
203.03%
Upside
Reiterated
03/10/26
Voyager Therapeutics: Undervalued Neurology Pipeline With High‑Reward 2026 Catalysts Supports Buy Rating
TD Cowen Analyst forecast on VYGR
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (NASDAQ: VYGR) and West Pharmaceutical Services (NYSE: WST)
Leerink Partners Analyst forecast on VYGR
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
$11
Buy
177.78%
Upside
Reiterated
12/15/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Voyager Therapeutics (NASDAQ: VYGR)
Oppenheimer Analyst forecast on VYGR
Jay Olson
Oppenheimer
Oppenheimer
$18
Buy
354.55%
Upside
Reiterated
10/02/25
Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer
Robert W. Baird Analyst forecast on VYGR
Jack Allen
Robert W. Baird
Robert W. Baird
$18
Buy
354.55%
Upside
Reiterated
07/17/25
Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Voyager Therapeutics

3 Months
xxx
Success Rate
7/16 ratings generated profit
44%
Average Return
-0.97%
reiterated a xxx
 rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of -0.97% per trade.
1 Year
Jack AllenRobert W. Baird
Not Ranked
Success Rate
11/22 ratings generated profit
50%
Average Return
-0.40%
reiterated a buy rating 9 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.40% per trade.
2 Years
xxx
Success Rate
9/18 ratings generated profit
50%
Average Return
-3.49%
reiterated a xxx
 rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -3.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VYGR Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
10
9
8
4
10
Buy
2
2
2
0
2
Hold
25
13
13
6
26
Sell
1
0
0
0
1
Strong Sell
0
0
0
0
0
total
38
24
23
10
39
In the current month, VYGR has received 12 Buy Ratings, 26 Hold Ratings, and 1 Sell Ratings. VYGR average Analyst price target in the past 3 months is 14.67.
Each month's total comprises the sum of three months' worth of ratings.

VYGR Financial Forecast

VYGR Earnings Forecast

Next quarter’s earnings estimate for VYGR is -$0.53 with a range of -$0.65 to -$0.28. The previous quarter’s EPS was -$0.46. VYGR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.
Next quarter’s earnings estimate for VYGR is -$0.53 with a range of -$0.65 to -$0.28. The previous quarter’s EPS was -$0.46. VYGR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.

VYGR Sales Forecast

Next quarter’s sales forecast for VYGR is $8.17M with a range of $2.00M to $18.30M. The previous quarter’s sales results were $15.34M. VYGR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.
Next quarter’s sales forecast for VYGR is $8.17M with a range of $2.00M to $18.30M. The previous quarter’s sales results were $15.34M. VYGR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VYGR has Performed in-line its overall industry.

VYGR Stock Forecast FAQ

What is VYGR’s average 12-month price target, according to analysts?
Based on analyst ratings, Voyager Therapeutics’s 12-month average price target is 14.67.
    What is VYGR’s upside potential, based on the analysts’ average price target?
    Voyager Therapeutics has 270.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VYGR a Buy, Sell or Hold?
          Voyager Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Voyager Therapeutics’s price target?
            The average price target for Voyager Therapeutics is 14.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $8.00. The average price target represents 270.45% Increase from the current price of $3.96.
              What do analysts say about Voyager Therapeutics?
              Voyager Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of VYGR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.